Vermillion, Inc. (NASDAQ:VRML) has been given a consensus broker rating score of 0.00 () from the zero analysts that cover the stock, Zacks Investment Research reports.
Zacks has also given Vermillion an industry rank of 170 out of 265 based on the ratings given to its competitors.
Separately, ValuEngine raised Vermillion from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd.
Shares of Vermillion (VRML) traded up 7.59% on Monday, hitting $1.70. The company’s stock had a trading volume of 34,809 shares. Vermillion has a 52 week low of $0.76 and a 52 week high of $2.85. The stock’s 50 day moving average price is $1.79 and its 200 day moving average price is $1.72. The stock’s market capitalization is $95.35 million.
Vermillion (NASDAQ:VRML) last posted its earnings results on Thursday, May 18th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The business had revenue of $0.73 million for the quarter. Vermillion had a negative return on equity of 195.68% and a negative net margin of 443.29%. On average, analysts forecast that Vermillion will post ($0.16) earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the stock. Oracle Investment Management Inc. increased its stake in shares of Vermillion by 7.2% in the first quarter. Oracle Investment Management Inc. now owns 9,241,956 shares of the company’s stock valued at $19,316,000 after buying an additional 617,731 shares in the last quarter. M&T Bank Corp increased its stake in shares of Vermillion by 48.2% in the first quarter. M&T Bank Corp now owns 230,500 shares of the company’s stock valued at $482,000 after buying an additional 75,000 shares in the last quarter. Greenwich Wealth Management LLC acquired a new stake in shares of Vermillion during the first quarter valued at about $276,000. Finally, Birchview Capital LP increased its stake in shares of Vermillion by 1.3% in the first quarter. Birchview Capital LP now owns 2,752,933 shares of the company’s stock valued at $5,649,000 after buying an additional 35,419 shares in the last quarter. 36.50% of the stock is currently owned by institutional investors.
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Vermillion Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vermillion Inc. and related companies.